Recommendation of the President – Mibrex (rivaroxaban)

On 30 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No.53/2025 on the appraisal of drug Mibrex (rivaroxaban) for the prevention of thrombotic events in adults with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are at high risk of ischemic events.

Publication in Public Information Bulletin (BIP) >>